# Deficiency for MicroRNA-582 does not impact dilated cardiomyopathy or heart failure induced by pressure overload in vivo

## TL;DR

This study finds that microRNA-582 does not significantly affect heart disease caused by pressure overload in mice.

## Contribution

The novel contribution is demonstrating that miR-582 is not a key player in pressure-induced heart failure or dilated cardiomyopathy in vivo.

## Key findings

- miR-582 overexpression or deficiency in mice did not alter baseline cardiac function.
- Pressure overload induced similar hypertrophy in miR-582 transgenic and knockout mice as in controls.
- Crossbreeding with CS1-KO mice did not change the dilated cardiomyopathy phenotype.

## Abstract

MicroRNAs (miRNAs) are critical post-transcriptional regulators of gene expression and have been extensively implicated in cardiovascular development, homeostasis, and disease. Among them, microRNA-582 (miR-582) has been associated with several non-cardiac pathologies, yet its role in the heart remains poorly characterized despite significant cardiac expression. In this study, we investigated the functional significance of miR-582 in cardiac pathophysiology through both gain- and loss-of-function approaches. We observed differential expression of miR-582 in murine models of cardiomyopathy, prompting further mechanistic evaluation. Thus, we generated transgenic mice with cardiac-specific overexpression of miR-582 (TG-582) as well as miR-582 knockout (582-KO) mice. Neither model exhibited an obvious cardiac phenotype under basal conditions. Following pressure overload via transverse aortic constriction (TAC), both TG-582 and 582-KO mice developed hypertrophy and functional adaptations comparable to wildtype controls. Additionally, crossbreeding these models with Calsarcin-1-knockout (CS1-KO) mice, a model of dilated cardiomyopathy, did not modify the pathological phenotype. These results indicate that miR-582 does not play a determinative role in pressure overload-induced cardiac hypertrophy or in the progression of dilated cardiomyopathy. Our findings highlight the importance of rigorously controlled in vivo studies to accurately define the cardiac miRNA landscape and to guide future therapeutic strategies.